WHO Sounds Concern Over Acute Scarcity of Weight-Loss Medications
Under one in 10 patients that would benefit from GLP-1 drugs like Wegovy are able to get them, states the World Health Organization as it issues its first recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.
Per estimates, over two billion will be living with obesity by 2030 unless action is taken.
"Our new guidelines recognises that obesity is a long-term condition that can be managed with thorough and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are major barriers to widespread access to the treatments that can assist patients in reducing considerable body mass, explains the organization.
GLP-1 Therapy Supply Crisis
Even in the current most favorable scenario, the manufacturing of such drugs might only reach about 100 million people – less than 10% of the global need, per the health organization.
The guideline calls on countries and companies to expand access, via strategies like licensing agreements.
The intellectual property rights on semaglutide – the main ingredient of Novo Nordisk's Wegovy – is due to expire in multiple countries in 2026.
The Way Weight-Loss Injections Work
GLP-1 drugs replicate a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so users consume fewer calories.
Individuals commonly start to lose weight in the initial weeks of beginning the weekly injections.
Studies indicates patients may regain a significant portion a year later of halting the drug, as their usual hunger come back.
To be overweight or obese increases your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and some cancers.
Excess weight concerns individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
